Neuronal pentraxin 1 Neuronal pentraxin 2 Hypoxia-ischemia Neonatal brain injury Oxygen glucose deprivation Mitochondria Bax Caspase-3 T2-weighted magnetic resonance imaging Neonatal hypoxic-ischemic (HI) brain injury is a leading cause of mortality and morbidity in infants and children for which there is no promising therapy at present. Previously, we reported induction of neuronal pentraxin 1 (NP1), a novel neuronal protein of the long-pentraxin family, following HI injury in neonatal brain. Here, we report that genetic deletion of NP1 expression prevents HI injury in neonatal brain. Elevated expression of NP1 was observed in neurons, not in astrocytes, of the ipsilateral cortical layers (I-IV) and in the hippocampal CA1 and CA3 areas of WT brains following hypoxia-ischemia; brain areas that developed infarcts (at 24-48 h), showed significantly increased numbers of TUNEL−(+) cells and tissue loss (at 7 days). In contrast, NP1-KO mice showed no evidence of brain infarction and tissue loss after HI. The immunofluorescence staining of brain sections with mitochondrial protein COX IV and subcellular fractionation analysis showed increased accumulation of NP1 in mitochondria, pro-death protein Bax activation and NP1 co-localization with activated caspase-3 in WT, but not in the NP1-KO brains; corroborating NP1 interactions with the mitochondria-derived pro-death pathways. Disruption of NP1 translocation to mitochondria by NP1-siRNA in primary cortical cultures significantly reduced ischemic neuronal death. NP1 was immunoprecipitated with activated Bax [6A7] proteins; HI caused increased interactions of NP1 with Bax, thereby, facilitating Bax translocation to mitochondrial and neuronal death. To further delineate the specificity of NPs, we found that NP1 but not the NP2 induction is specifically involved in brain injury mechanisms and that knockdown of NP1 only results in neuroprotection. Furthermore, live in vivo T2-weighted magnetic resonance imaging (MRI) including fractional anisotropy (FA) mapping showed no sign of delayed brain injury or tissue loss in the NP1-KO mice as compared to the WT at different post-HI periods (4-24 weeks) examined; indicating a long-term neuroprotective efficacy of NP1 gene deletion. Collectively, our results demonstrate a novel mechanism of neuronal death and predict that inhibition of NP1 expression is a promising strategy to prevent hypoxic-ischemic injury in immature brain.
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Introduction
Perinatal/neonatal hypoxic-ischemic brain injury is the leading cause of long-term disabilities and neurological disorders (Johnston, 1997; Lorenz et al., 1998; Northington et al., 2011) . Neonatal brain injury following hypoxia-ischemia (HI) occurs at a rate of about three per thousand live-born infants (Johnston, 2005; Johnston et al., 2011) ; affecting the life of all ages and population including patient, care-takers and the family. However, current treatment regimens are not optimal. A number of clinical trials have focused on new therapies, however, very few trials have documented limited clinical benefits due to lack of understanding of the discrete cellular and molecular factors and signaling pathways involved in brain injury mechanisms (Blomgren and Hagberg, 2006; Kalenderian et al., 2009; Pezzini and Padovani, 2009) .
Discoveries of the role of the α-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid (AMPA) and N-methyl-D-aspartic acid (NMDA) glutamate receptor-mediated excitotoxicity, oxidative stress, and cell-death signaling pathways have provided a platform for understanding neonatal brain injury (Barks and Silverstein, 1992; Choi and Rothman, 1990; Hossain et al., 1998; Portera-Cailliau et al., 1997) . Among the candidate target molecules considered to act as early mediators of AMPAR-recruitment and clustering at synaptic sites include members of the neuronal pentraxin family; neuronal pentraxin 1 (NP1), neuronal activity-regulated pentraxin (Narp; also called NP2), and neuronal pentraxin receptor (NPR), and NPs are exclusively expressed in neurons (Goodman et al., 1996; Schlimgen et al., 1995; Neurobiology of Disease 75 (2015) 15-30 
